Class Action Filed Against Organon & Co. (OGN) Seeking Recovery for Investors - Contact Levi & Korsinsky

1. Organon faces class action lawsuit over alleged securities fraud affecting investors. 2. Defendants allegedly concealed facts about capital allocation and debt reduction strategies. 3. OGN's stock dropped 27% from $12.93 to $9.45 in one day post-announcement. 4. Investors can seek compensation without upfront costs for losses incurred from Oct 2024-Apr 2025. 5. The lawsuit emphasizes the risk and volatility associated with OGN's stock.

Legal

80

5m saved

Insight

Article

FAQ

Why Very Bearish?

The substantial stock price drop and class action lawsuit indicate significant investor distrust and potential financial liabilities that could severely impact OGN's market position, reminiscent of historical cases where similar class actions led to long-term stock depressions.

How important is it?

The class action lawsuit's potential financial impact and the strategic mismanagement indicated have serious implications for company performance and investor confidence, making it highly relevant for OGN stockholders.

Why Short Term?

The immediate market reaction post-announcement suggests that investor sentiment could remain negative in the short term, although long-term recovery might be possible should leadership address the underlying issues.

Related Companies

DERM JNJ PFE

NEW YORK, June 13, 2025 /PRNewswire/ --

Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit.

CLASS DEFINITION:

The lawsuit seeks to recover losses on behalf of Organon investors who were adversely affected by alleged securities fraud between October 31, 2024 and April 30, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=152773&wire=4

OGN investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS:

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Organon's priorities, particularly, related to capital allocation through quarterly dividends. Notably, defendants concealed the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. Following this news, the price of Organon's common stock declined dramatically. From a closing market price of $12.93 per share on April 30, 2025, Organon's stock price fell to $9.45 per share on May 1, 2025, a decline of more than 27% in the span of just a single day.

WHAT'S NEXT?

If you suffered a loss in Organon during the relevant time frame, you have until July 22, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU:

If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY:

Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE Levi & Korsinsky, LLP